Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+41-61-3241111
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
Next Earnings DateN/A
OptionableNot Optionable
Novartis (VTX:NOVN) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the VTX under the ticker symbol "NOVN."
What price target have analysts set for NOVN?
14 equities research analysts have issued twelve-month price objectives for Novartis' stock. Their forecasts range from CHF 79 to CHF 105. On average, they anticipate Novartis' share price to reach CHF 89.71 in the next twelve months. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
News articles about NOVN stock have trended positive on Tuesday, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Novartis.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ) and Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP).
What other stocks do shareholders of Novartis own?
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 60)
- Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
- Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
- Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
- Dr. Carri Geer, Sr. VP & CTO
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.
MarketBeat Community Rating for Novartis (VTX NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
